tiprankstipranks
Trending News
More News >
Philogen SpA (IT:PHIL)
:PHIL

Philogen SpA (PHIL) AI Stock Analysis

Compare
8 Followers

Top Page

IT

Philogen SpA

(Stuttgart:PHIL)

Rating:75Outperform
Price Target:
€25.00
▲(13.12%Upside)
Philogen SpA's strong financial performance, marked by significant revenue growth and a solid balance sheet, is the primary driver of its high score. While the technical indicators present a mixed outlook, the company's fair valuation supports the potential for future growth. The absence of earnings call data and corporate events does not significantly impact the overall score.
Positive Factors
Financial growth
Philogen expects to triple its revenues as a result of the partnership agreement with Sun Pharma, highlighting strong financial growth prospects.
Partnerships
Philogen announced a global licensing agreement with RayzeBio, granting development, manufacturing and commercialization rights to OncoACP3, a small molecule radiopharmaceutical targeting prostate cancer.
Negative Factors
Market perception
The analyst continues to see the company’s late stage pipeline as underappreciated by the market.

Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)

Philogen SpA Business Overview & Revenue Model

Company DescriptionPhilogen SpA (PHIL) is a biotechnology company focused on the discovery and development of novel pharmaceutical and diagnostic products. The company operates primarily within the healthcare sector, specializing in the research and development of targeted therapies for the treatment of cancer and inflammatory disorders. Philogen utilizes its proprietary technologies to create innovative products aimed at improving patient outcomes.
How the Company Makes MoneyPhilogen SpA generates revenue primarily through the development and commercialization of its pharmaceutical products. The company engages in partnerships and collaborations with other pharmaceutical and biotechnology firms to advance its clinical programs and to co-develop therapeutics. These partnerships often include licensing agreements, milestone payments, and royalties based on sales of co-developed products. Additionally, Philogen may receive funding from grants and research collaborations, contributing to its revenue streams. The company's earnings are largely driven by the successful development and market approval of its therapeutic candidates.

Philogen SpA Financial Statement Overview

Summary
Philogen SpA demonstrates excellent financial performance in 2024, with strong revenue growth and margin improvements. The company turned profitable with a net profit margin of 58.3%, and the balance sheet is debt-free with a robust equity base. Cash flows are positive and well-managed, supporting operational and investment activities.
Income Statement
85
Very Positive
Philogen SpA shows strong revenue growth with a significant increase from €23.1M in 2023 to €77.6M in 2024. The gross profit margin improved drastically from 24.5% in 2023 to 53.6% in 2024. The company turned profitable with a net profit margin of 58.3% in 2024, a remarkable recovery from previous losses. EBIT and EBITDA margins also improved to 53.6% in 2024, reflecting efficient cost management.
Balance Sheet
78
Positive
The balance sheet is strong with no debt in 2024, improving the debt-to-equity ratio to 0. The equity ratio is robust at 88.4%, indicating a solid equity base. However, the total assets increased less significantly compared to equity, which may limit leverage opportunities.
Cash Flow
80
Positive
Philogen's free cash flow turned positive in 2024, with a substantial increase to €38.7M from a negative position in 2023. The operating cash flow to net income ratio is 0.90, indicating efficient cash generation relative to net earnings. The free cash flow to net income ratio is 0.85, showing strong cash flow management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue74.00M23.13M23.71M2.50M4.78M
Gross Profit54.42M5.67M10.53M-8.14M-5.05M
EBITDA44.75M-2.05M-1.19M-12.98M-10.53M
Net Income45.29M-6.16M-5.38M-15.72M-13.29M
Balance Sheet
Total Assets168.45M119.27M125.83M132.75M85.47M
Cash, Cash Equivalents and Short-Term Investments113.73M75.34M86.20M101.68M61.94M
Total Debt11.51M14.91M11.89M11.84M11.98M
Total Liabilities29.80M28.68M27.91M27.67M29.80M
Stockholders Equity138.66M90.59M97.92M105.09M55.67M
Cash Flow
Free Cash Flow38.67M-10.69M-9.15M-25.85M-16.81M
Operating Cash Flow40.84M-4.82M-4.94M-19.03M-13.16M
Investing Cash Flow-22.28M159.00K24.20M-47.77M17.77M
Financing Cash Flow-3.78M-4.17M-3.78M63.05M3.79M

Philogen SpA Technical Analysis

Technical Analysis Sentiment
Negative
Last Price22.10
Price Trends
50DMA
23.12
Negative
100DMA
21.06
Positive
200DMA
20.25
Positive
Market Momentum
MACD
0.36
Positive
RSI
35.32
Neutral
STOCH
4.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Negative. The current price of 22.1 is below the 20-day moving average (MA) of 24.72, below the 50-day MA of 23.12, and above the 200-day MA of 20.25, indicating a neutral trend. The MACD of 0.36 indicates Positive momentum. The RSI at 35.32 is Neutral, neither overbought nor oversold. The STOCH value of 4.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHIL.

Philogen SpA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
€672.59M20.1139.51%219.91%
ITPHN
66
Neutral
€448.71M27.13
1.85%17.78%63.72%
51
Neutral
$7.41B0.32-61.11%2.34%16.99%1.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:PHIL
Philogen SpA
22.10
1.70
8.33%
IT:PHN
PharmaNutra SpA
46.35
-0.33
-0.71%

Philogen SpA Corporate Events

Philogen Withdraws Nidlegy™ Application from EMA, Plans Resubmission
Jun 25, 2025

Philogen has decided to withdraw its marketing authorization application for Nidlegy™, a treatment for locally advanced melanoma, from the European Medicines Agency due to delays in providing necessary data. Despite this setback, Philogen remains confident in Nidlegy™’s efficacy and safety profile, and plans to resubmit the application with updated data to make the treatment available for both melanoma and non-melanoma skin cancer patients.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philochem Licenses Prostate Cancer Agent to RayzeBio in $1.35 Billion Deal
Jun 10, 2025

Philogen’s subsidiary, Philochem AG, has licensed the worldwide rights to OncoACP3, a new therapeutic and diagnostic agent for prostate cancer, to RayzeBio, a Bristol-Myers Squibb subsidiary, in a deal worth up to $1.35 billion plus royalties. This agreement marks a significant milestone, enhancing RayzeBio’s position in the radiopharmaceutical sector and promising a groundbreaking treatment option for prostate cancer, with Philochem receiving an initial payment and potential milestone payments, subject to regulatory approvals expected by the third quarter of 2025.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates on Share Buyback Program
Jun 3, 2025

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 790 shares at an average price of Euro 22.50 per share, totaling Euro 17,775.00. Since the program’s inception, the company has acquired 14,742 shares, representing 0.0363% of its share capital, which may impact its market positioning and shareholder value.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Releases Shareholders’ Meeting Minutes
May 26, 2025

Philogen S.p.A. has made available the minutes of its Shareholders’ Meeting held on April 29, 2025. This announcement underscores the company’s commitment to transparency and governance, potentially reinforcing stakeholder confidence and supporting its strategic objectives in the biotechnology sector.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Updates on Share Buyback Program
May 26, 2025

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 1,800 shares between May 19 and May 23, 2025, at an average price of Euro 22.30 per share, totaling Euro 40,140.00. Since the program’s inception, the company has acquired 13,952 shares, representing 0.0344% of its share capital, with a total value of Euro 309,433.85. This move is part of Philogen’s strategy to manage its capital structure and potentially increase shareholder value, reflecting confidence in its ongoing operations and future prospects.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates Share Buyback Program with Recent Purchases
May 19, 2025

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 7,628 shares between May 12 and May 16, 2025, at an average price of Euro 22.3742 per share, totaling Euro 170,670.65. This move is part of a broader strategy to enhance shareholder value and demonstrates the company’s commitment to its investors. The buyback program, since its inception, has seen the acquisition of 12,152 shares, representing 0.0299% of the share capital, indicating Philogen’s proactive approach in managing its equity and reinforcing its market position.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Updates on Share Buyback Program
May 12, 2025

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 4,524 shares from May 7 to May 9, 2025, representing 0.0111% of its share capital at an average price of Euro 21.80 per share. This move is part of a broader strategy approved by the Board of Directors and Shareholders’ Meeting, reflecting the company’s commitment to enhancing shareholder value. As of May 9, 2025, Philogen holds a total of 336,674 ordinary shares, equating to 0.8290% of its share capital, indicating a strategic approach to managing its equity and potentially impacting its market positioning.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Reports Strong Financial Position and Progress in Clinical Trials
May 6, 2025

Philogen S.p.A. reported a positive net financial position of €93.574 million for the first quarter of 2025, despite a decrease from the previous quarter. The company is progressing with its main trials, Nidlegy™ and Fibromun, and has initiated a share buyback program. The Board of Directors has also reconstituted key committees and noted significant advancements in their industrial programs. These developments reflect Philogen’s strategic focus on expanding its clinical pipeline and maintaining financial stability, which could enhance its position in the biopharmaceutical industry.

Philogen S.p.A. Approves 2024 Financials and Appoints New Board
Apr 29, 2025

Philogen S.p.A.’s Shareholders’ Meeting approved the 2024 financial statements, allocating a net profit of over 45 million euros to reserves. The meeting also appointed a new Board of Directors, with Dr. Duccio Neri as Chairman, and approved amendments to incentive plans for employees and directors, including a stock grant plan and a shareholding plan.

Philogen S.p.A. Advances Share Buyback Program with Latest Acquisition
Apr 14, 2025

Philogen S.p.A. announced the purchase of 6,120 of its own shares as part of its ongoing share buyback program, approved by the Board of Directors in December 2024. This transaction, conducted on the Euronext Milan market, represents 0.0151% of the company’s share capital. Since the start of the buyback program, Philogen has acquired a total of 55,776 shares, equivalent to 0.1373% of its share capital, reflecting a strategic move to consolidate its market position and potentially enhance shareholder value.

Philogen Announces Voting Rights Ahead of Shareholders’ Meeting
Apr 11, 2025

Philogen S.p.A. has announced the total amount of voting rights ahead of its upcoming Shareholders’ Meeting. The company disclosed that its share capital consists of 40,611,111 shares, translating to 63,347,611 voting rights. This announcement underscores Philogen’s commitment to transparency and provides stakeholders with crucial information about its governance structure, potentially impacting investor confidence and market perception.

Philogen S.p.A. Proposes New Board of Directors
Apr 7, 2025

Philogen S.p.A. has announced the submission of a list of candidates for the appointment of its Board of Directors, which will be decided at the upcoming shareholders’ meeting. The list, presented by major shareholder Nerbio S.r.l., includes ten candidates, with Dr. Duccio Neri proposed as Chairman. This move is part of the company’s adherence to regulatory and statutory provisions, ensuring compliance with governance codes, and aims to solidify its leadership structure.

Philogen Updates on Share Buyback Program
Apr 7, 2025

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 8,199 shares, representing 0.0202% of its share capital, for a total of Euro 162,240.01 between March 31 and April 4, 2025. This move is part of a broader strategy to manage its capital structure, with the company having acquired a total of 49,656 shares since the program’s inception. The buyback program reflects Philogen’s commitment to enhancing shareholder value and optimizing its financial resources.

Philogen Updates Share Buyback Program, Strengthening Market Position
Mar 31, 2025

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 6,473 shares between March 24 and March 28, 2025, at an average price of Euro 19.4810 per share, totaling Euro 126,100.61. This move is part of a broader strategy to manage capital structure, with the company having acquired a total of 41,457 shares since the program’s inception. The buyback program reflects Philogen’s confidence in its market positioning and aims to enhance shareholder value.

Philogen Publishes Shareholders’ Meeting Documentation for April 2025
Mar 28, 2025

Philogen S.p.A. has released documentation related to its upcoming shareholders’ meeting on April 29, 2025. The documents include explanatory reports on various agenda items such as financial statements, remuneration policy, incentive plans, and proposals for share capital increase. These documents are available on the company’s website and through authorized storage mechanisms. The announcement highlights Philogen’s ongoing efforts to engage with shareholders and manage its financial and strategic planning, potentially impacting its market position and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025